These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25822882)

  • 1. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
    Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of regulatory T cells that modulate vascular inflammation.
    Franco A; Touma R; Song Y; Shimizu C; Tremoulet AH; Kanegaye JT; Burns JC
    Autoimmunity; 2014 Mar; 47(2):95-104. PubMed ID: 24490882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
    Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease.
    Hirabayashi Y; Takahashi Y; Xu Y; Akane K; Villalobos IB; Okuno Y; Hasegawa S; Muramatsu H; Hama A; Kato T; Kojima S
    Eur J Pediatr; 2013 Jun; 172(6):833-7. PubMed ID: 23340699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q; Gong FQ; Shang SQ; Hu J
    Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
    Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease.
    Wang CL; Wu YT; Liu CA; Lin MW; Lee CJ; Huang LT; Yang KD
    Pediatrics; 2003 Feb; 111(2):E140-7. PubMed ID: 12563087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R; Inuzuka R; Shindo T; Namai Y; Oda Y; Harita Y; Oka A
    Clin Rheumatol; 2020 Dec; 39(12):3747-3755. PubMed ID: 32458247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
    Hsieh LE; Song J; Tremoulet AH; Burns JC; Franco A
    Clin Exp Immunol; 2022 Jun; 208(3):361-371. PubMed ID: 35536993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH; Huang YC; Yen MH; Li CC; Chiu CH; Lin PY; Lin TY; Chang LY
    J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
    Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
    Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Uittenbogaard P; Netea SA; Tanck MWT; Geissler J; Buda P; Kowalczyk-Domagała M; Okarska-Napierała M; van Stijn D; Tacke CE; ; Burgner DP; Shimizu C; Burns JC; Kuipers IM; Kuijpers TW; Nagelkerke SQ
    Front Immunol; 2024; 15():1323171. PubMed ID: 39359734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
    Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of FcRs on monocytes among Kawasaki disease patients with coronary artery lesions.
    Xia Y; Tian X; Li Q; Wang G; Li C; Yang J
    Int Immunopharmacol; 2017 Apr; 45():1-5. PubMed ID: 28147297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.
    Burns JC; Franco A
    Expert Rev Clin Immunol; 2015; 11(7):819-25. PubMed ID: 26099344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.